DTDierk Thomas

Dierk Thomas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dierk Thomas has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Johann Kiehn

    Department of Cardiology, Medical University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany

    7 shared publications
  • Wolfgang Schoels

    Department of Cardiology, Medical University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany

    7 shared publications
  • Hugo A. Katus

    Department of Cardiology

    6 shared publications
  • Kezhong Wu

    Department of Cardiology, Medical University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany

    6 shared publications
  • Christoph A. Karle

    Department of Cardiology, Medical University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany

    5 shared publications
  • Anna-Britt Wimmer

    Department of Cardiology, Medical University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany

    4 shared publications

Latest Publications

  • Open Access

    Systemic Embolization and Myocardial Infarction due to Clinically Unrecognized Left Atrial Myxoma

    by Britta Vogel, Dierk Thomas, Derliz Mereles, Wolfgang Rottbauer, Hugo A. Katus

    Myxomas are the most common primary tumors of the heart. We report an extraordinary severe case of left atrial myxoma, presenting with stroke, myocardial infarction, and multiple arterial embolism including aorta, splenic and renal arteries, and several peripheral arteries. The patient had previously been diagnosed with systemic vasculitis, a typical but less common finding caused by multiple emboli mimicking vasculitis. The myxoma was removed and atrial septum reconstruction was performed. In summary, early diagnostic differentiation of myxoma from vasculitis is critical, and immediate surgical removal of myxoma is required as the probability of thromboembolic complications increases over time.


  • Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X)

    by Dierk Thomas, Bettina C. Hammerling, Anna-Britt Wimmer, Kezhong Wu, Eckhard Ficker, Yuri A. Kuryshev, Daniel Scherer, Johann Kiehn, Hugo A. Katus, Wolfgang Schoels, et al.

    The human ether-a-go-go-related gene (hERG) encodes the rapid component of the cardiac repolarizing delayed rectifier potassium current, I(Kr). The direct interaction of the commonly used protein kinase C (PKC) inhibitor bisindolylmaleimide I (BIM I) with hERG, KvLQT1/minK, and I(Kr) currents was investigated in this study. hERG and KvLQT1/minK channels were heterologously expressed in Xenopus laevis oocytes, and currents were measured using the two-microelectrode voltage clamp technique. In addition, hERG currents in stably transfected human embryonic kidney (HEK 293) cells, native I(Kr) currents and action potentials in isolated guinea pig ventricular cardiomyocytes were recorded using whole-cell patch clamp electrophysiology. Bisindolylmaleimide I blocked hERG currents in HEK 293 cells and Xenopus oocytes in a concentration-dependent manner with IC(50) values of 1.0 and 13.2 muM, respectively. hERG channels were primarily blocked in the open state in a frequency-independent manner. Analysis of the voltage-dependence of block revealed a reduction of inhibition at positive membrane potentials. BIM I caused a shift of -20.3 mV in the voltage-dependence of inactivation. The point mutations tyrosine 652 alanine (Y652A) and phenylalanine 656 alanine (F656A) attenuated hERG current blockade, indicating that BIM I binds to a common drug receptor within the pore region. KvLQT1/minK currents were not significantly altered by BIM I. Finally, 1 muM BIM I reduced native I(Kr) currents by 69.2% and lead to action potential prolongation. In summary, PKC-independent effects have to be carefully considered when using BIM I as PKC inhibitor in experimental models involving hERG channels and I(Kr) currents.


  • Activation of cardiac human ether-a-go-go related gene potassium currents is regulated by ?1A-adrenoceptors

    by Dierk Thomas, Kezhong Wu, Anna-Britt Wimmer, Edgar Zitron, Bettina C. Hammerling, Sven Kathöfer, Sonja Lueck, Ramona Bloehs, Volker A. W. Kreye, Johann Kiehn, et al.

    Patients with cardiac disease typically develop life-threatening ventricular arrhythmias during physical or emotional stress, suggesting a link between adrenergic stimulation and regulation of the cardiac action potential. Human ether-a-go-go related gene (hERG) potassium channels conduct the rapid component of the repolarizing delayed rectifier potassium current, IKr. Previous studies have revealed that hERG channel activation is modulated by activation of the β-adrenergic system. In contrast, the influence of the α-adrenergic signal transduction cascade on hERG currents is less well understood. The present study examined the regulation of hERG currents by α1A-adrenoceptors. hERG channels and human α1A-adrenoceptors were heterologously coexpressed in Xenopus laevis oocytes, and currents were measured using the two-microelectrode voltage clamp technique. Stimulation of α1A-receptors by applying 20 µM phenylephrine caused hERG current reduction due to a 9.6-mV shift of the activation curve towards more positive potentials. Simultaneous application of the α1-adrenoceptor antagonist prazosin (20 µM) prevented the activation shift. Inhibition of PKC (3 µM Ro-32-0432) or PKA (2.5 µM KT 5720) abolished the α-adrenergic activation shift, suggesting that PKC and PKA are required within the regulatory mechanism. The effect was still present when the PKA- and PKC-dependent phosphorylation sites in hERG were deleted by mutagenesis. In summary, cardiac repolarizing hERG/IKr potassium currents are modulated by α1A-adrenoceptors via PKC and PKA independently of direct channel phosphorylation. This novel regulatory pathway of α1-adrenergic hERG current regulation provides a link between stress and ventricular arrhythmias, in particular in patients with heart disease.


  • Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action

    by Dierk Thomas, Bettina C Hammerling, Kezhong Wu, Anna‐Britt Wimmer, Eckhard K Ficker, Glenn E Kirsch, Mary C Kochan, Barbara A Wible, Eberhard P Scholz, Edgar Zitron, et al.

    The topoisomerase II inhibitor amsacrine is used in the treatment of acute myelogenous leukemia. Although most anticancer drugs are believed not to cause acquired long QT syndrome (LQTS), concerns have been raised by reports of QT interval prolongation, ventricular fibrillation and death associated with amsacrine treatment. Since blockade of cardiac human ether‐a‐go‐go‐related gene (HERG) potassium currents is an important cause of acquired LQTS, we investigated the acute effects of amsacrine on cloned HERG channels to determine the electrophysiological basis for its proarrhythmic potential. HERG channels were heterologously expressed in human HEK 293 cells and Xenopus laevis oocytes, and the respective potassium currents were recorded using patch‐clamp and two‐microelectrode voltage‐clamp electrophysiology. Amsacrine blocked HERG currents in HEK 293 cells and Xenopus oocytes in a concentration‐dependent manner, with IC50 values of 209.4 nM and 2.0 μM, respectively. HERG channels were primarily blocked in the open and inactivated states, and no additional voltage dependence was observed. Amsacrine caused a negative shift in the voltage dependence of both activation (−7.6 mV) and inactivation (−7.6 mV). HERG current block by amsacrine was not frequency dependent. The S6 domain mutations Y652A and F656A attenuated (Y652A) or abolished (F656A, Y652A/F656A) HERG current blockade, indicating that amsacrine binding requires a common drug receptor within the pore‐S6 region. In conclusion, these data demonstrate that the anticancer drug amsacrine is an antagonist of cloned HERG potassium channels, providing a molecular mechanism for the previously reported QTc interval prolongation during clinical administration of amsacrine. British Journal of Pharmacology (2004) 142, 485–494. doi:10.1038/sj.bjp.0705795


  • Inhibition of human ether-a-go-go-related gene potassium channels by a1-adrenoceptor antagonists prazosin, doxazosin, and terazosin

    by Dierk Thomas, Anna-Britt Wimmer, Kezhong Wu, Bettina C. Hammerling, Eckhard K. Ficker, Yuri A. Kuryshev, Johann Kiehn, Hugo A. Katus, Wolfgang Schoels, Christoph A. Karle

    Human ether-a-go-go-related gene (HERG) potassium channels are expressed in multiple tissues including the heart and adenocarcinomas. In cardiomyocytes, HERG encodes the α-subunit underlying the rapid component of the delayed rectifier potassium current, IKr, and pharmacological reduction of HERG currents may cause acquired long QT syndrome. In addition, HERG currents have been shown to be involved in the regulation of cell proliferation and apoptosis. Selective α1-adrenoceptor antagonists are commonly used in the treatment of hypertension and benign prostatic hyperplasia. Recently, doxazosin has been associated with an increased risk of heart failure. Moreover, quinazoline-derived α1-inhibitors induce apoptosis in cardiomyocytes and prostate tumor cells independently of α1-adrenoceptor blockade. To assess the action of the effects of prazosin, doxazosin, and terazosin on HERG currents, we investigated their acute electrophysiological effects on cloned HERG potassium channels heterologously expressed in Xenopus oocytes and HEK 293 cells. Prazosin, doxazosin, and terazosin blocked HERG currents in Xenopus oocytes with IC50 values of 10.1, 18.2, and 113.2 μM respectively, whereas the IC50 values for HERG channel inhibition in human HEK 293 cells were 1.57 µM, 585.1 nM, and 17.7 µM. Detailed biophysical studies revealed that inhibition by the prototype α1-blocker prazosin occurred in closed, open, and inactivated channels. Analysis of the voltage-dependence of block displayed a reduction of inhibition at positive membrane potentials. Frequency-dependence was not observed. Prazosin caused a negative shift in the voltage-dependence of both activation (−3.8 mV) and inactivation (−9.4 mV). The S6 mutations Y652A and F656A partially attenuated (Y652A) or abolished (F656A) HERG current blockade, indicating that prazosin binds to a common drug receptor within the pore-S6 region. In conclusion, this study demonstrates that HERG potassium channels are blocked by prazosin, doxazosin, and terazosin. These data may provide a hypothetical molecular explanation for the apoptotic effect of quinazoline-derived α1-adrenoceptor antagonists.


  • Adrenergic regulation of the rapid component of the cardiac delayed rectifier potassium current, IKr, and the underlying hERG ion channel

    by Dierk Thomas, Johann Kiehn, Hugo A. Katus, Christoph A. Karle

    Ventricular arrhythmias are often precipitated by physical or emotional stress, in particular in patients with ischemic heart disease or hereditary long QT syndrome. Stimulation of the sympathetic nervous system in response to exercise or emotional stress causes activation of cardiac α- and β-adrenoceptors. The rapid component of the delayed rectifier potassium current, IKr, and the underlying hERG potassium channel are critical for the regulation of heart rhythm. Recent experimental studies revealed that hERG/IKr currents are modulated by α- and β-adrenergic stimulation, providing a pathophysiological explanation for the increased incidence of arrhythmias during stress. This review summarizes the current knowledge on hERG/IKr channel modulation by adrenergic activity. In addition, therapeutic approaches to future effective, more genotype-specific antiarrhythmic therapies are discussed.


  • Modulation of HERG potassium channel function by drug action

    by Dierk Thomas, Christoph Karle, Johann Kiehn

    Repolarization of cardiomyocytes is mainly performed by the rapid component of the delayed rectifier potassium current, I Kr , which is encoded by the human ether‐a‐go‐go‐related gene (HERG). Inhibition of HERG potassium currents by class III antiarrhythmic drugs causes lengthening of the cardiac action potential, which produces a beneficial antiarrhythmic effect. Conversely, excessive prolongation of the action potential by a wide variety of antiarrhythmic and non‐antiarrhythmic drugs may lead to acquired long‐QT syndrome, which is associated with a risk for ‘torsade de pointes’‐arrhythmias and sudden cardiac death. As a result, this undesirable side effect has prompted the withdrawal of several drugs from the market. Recent studies on HERG channel inhibition provide significant insights into the molecular factors that determine state‐, voltage‐, and use‐dependency of HERG current block. In addition, crucial properties of the putative drug binding site in HERG have been identified. The broad diversity in response to pharmacologic treatment among individuals is likely to depend on a combination of multiple factors from the fields of arrhythmia genetics, physiology and pharmacology. In conclusion, the increasing understanding of the molecular mechanisms that underlie HERG channel block by antiarrhythmic and non‐antiarrhythmic drugs may improve prevention and treatment of drug‐induced long‐QT syndrome.


  • Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing

    by D Thomas

    Human hereditary long QT syndrome is a cardiac disease characterized by prolongation of the QT interval and increased susceptibility to ventricular arrhythmias and sudden cardiac death. Mutations in the human-ether-a-go-go-related gene (hERG), encoding the protein underlying the repolarizing cardiac I(Kr) potassium current, cause chromosome 7-linked long QT syndrome 2. Loss of function of mutant hERG channels may be caused by several mechanisms, including altered current kinetics, altered ion selectivity, or defective intracellular protein trafficking. Especially the latter category has become a focus of particular interest recently, because some of the mutant subunits display wild type current properties when normal trafficking is restored and channels are inserted in the cell membrane in vitro. This review summarizes the current knowledge on hERG channel trafficking under physiological and pathological conditions. In addition, therapeutic approaches to restore normal hERG trafficking in vitro and in vivo are discussed.


  • Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels

    by Dierk Thomas, Sven Kathöfer, Wei Zhang, Kezhong Wu, Anna‐Britt Wimmer, Edgar Zitron, Volker A W Kreye, Hugo A Katus, Wolfgang Schoels, Christoph A Karle, et al.

    Dronedarone is a noniodinated benzofuran derivative that has been synthesized to overcome the limiting iodine‐associated adverse effects of the potent antiarrhythmic drug amiodarone. In this study, the acute electrophysiological effects of dronedarone on repolarizing potassium channels were investigated to determine the class III antiarrhythmic action of this compound. HERG and KvLQT1/minK potassium channels conduct the delayed rectifier potassium current IK in human heart, being a primary target for class III antiarrhythmic therapy. HERG and KvLQT1/minK were expressed heterologously in Xenopus laevis oocytes, and the respective potassium currents were recorded using the two‐microelectrode voltage‐clamp technique. Dronedarone blocked HERG channels with an IC50 value of 9.2 μM and a maximum tail current reduction of 85.2%. HERG channels were blocked in the closed, open, and inactivated states. The half‐maximal activation voltage was shifted by −6.1 mV, and HERG current block by dronedarone was voltage‐dependent, but not use‐dependent. Dronedarone exhibited a weaker block of KvLQT1/minK currents (33.2% at 100 μM drug concentration), without causing significant changes in the corresponding current–voltage relationships. In conclusion, these data demonstrate that dronedarone is an antagonist of cloned HERG potassium channels, with additional inhibitory effects on KvLQT1/minK currents at higher drug concentrations, providing a molecular mechanism for the class III antiarrhythmic action of the drug. British Journal of Pharmacology (2003) 140, 996–1002. doi:10.1038/sj.bjp.0705502